Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Because of its role in the regulation of the cell cycle, DNA damage response, apoptosis, DNA repair, cell migration, autophagy, and cell metabolism, the TP53 tumor suppressor gene is a key player for cellular homeostasis. TP53 gene is mutated in more than 50% of human cancers, although its overall dysfunction may be even more frequent. TP53 mutations are detected in a lower percentage of hematological malignancies compared to solid tumors, but their frequency generally increases with disease progression, generating adverse effects such as resistance to chemotherapy. Due to the crucial role of P53 in therapy response, several molecules have been developed to re-establish the wild-type P53 function to mutant P53. PRIMA-1 and its methylated form PRIMA-1Met (also named APR246) are capable of restoring the wild-type conformation to mutant P53 and inducing apoptosis in cancer cells; however, they also possess mutant P53-independent properties. This review presents the activities of PRIMA-1 and PRIMA-1Met/APR246 and describes their potential use in hematological malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Specifically, the concentration and timing of drug administration significantly impact therapeutic responses.”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [338]
In the citing paper
“For example, APR-246 works by reducing intracellular glutathione levels and increasing reactive oxygen species (ROS) levels, but this mechanism may be affected by other metabolic pathways within the cell.326,338”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [338]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“To achieve these goals, P53 binds, as a tetrameric transcription factor, to conserved response elements (REs) located in the promoter regions of target genes, including P21 and GADD45A for the cell cycle arrest, BAX, PUMA and NOXA for the induction of apoptosis, thus activating their expression and counteracting cance…”
Background2016 US lymphoid malignancy statistics by World Health Organization subtypes
Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A., & Flowers, C. R. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21357 · Cited by 1,125 · cited 1×
“CLL represents approximately 30% of all adult leukemias [28] and is characterized by a clonal expansion of small, relatively monomorphic circulating B cells, which may infiltrate the bone marrow, the lymph nodes, and the spleen [29].”
BackgroundRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 14×
“Although APR246 has received breakthrough therapy, orphan drug and fast track designations from the FDA for MDS, and Orphan Drug designation from the European Commission for MDS, AML, and ovarian cancer, it has not yet been approved by the FDA or any regulatory authority.”
BackgroundInfluentialVenetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Seymour, J. F., Kipps, T. J., Eichhorst, B., Hillmen, P., D’Rozario, J., Assouline, S., Owen, C., Gerecitano, J., Robak, T., De la Serna, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713976 · Cited by 940
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889 · cited 1×
“Nowadays, three main strategies are available, including (i) the restoration of wild-type P53 activity by inhibiting its binding with MDM2/4 proteins [9,10]; (ii) the reactivation of the wild-type function in the mutant P53 protein [11] and (iii) the elimination of the undesired GOF activities through degradation of t…”
MethodPRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · cited 2×
“Ten patients could be further evaluated, two of them showing signs of tumor regression [93].”
BackgroundInhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation
Liu, D. S., Duong, C. P., Haupt, S., Montgomery, K. G., House, C. M., Azar, W. J., Pearson, H. B., Fisher, O. M., Read, M., Guerra, G. R., et al. (2017) · Nature Communications · doi:10.1038/ncomms14844 · Cited by 321 · cited 3×
“Therefore, cells with high SLC7A11 levels are expected to be resistant, while those with low SLC7A11 expression to be sensitive to APR246, indicating SLC7A11 as a response predictor, as demonstrated in cells from the esophageal carcinoma and in cells from the NCI-60 cell lines panel, representing different solid and h…”
BackgroundAPR-246 reactivates mutant p53 by targeting cysteines 124 and 277
Zhang, Q., Bykov, V. J. N., Wiman, K. G., & Zawacka-Pankau, J. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0463-7 · Cited by 261
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183
Peng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.417 · Cited by 170
PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance
Tessoulin, B., Descamps, G., Moreau, P., Maïga, S., Lodé, L., Godon, C., Marionneau-Lambot, S., Oullier, T., Le Gouill, S., Amiot, M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548800 · Cited by 166
Regulation of p53: a collaboration between Mdm2 and MdmX
Pei, D., Zhang, Y., & Zheng, J. (2012) · Oncotarget · doi:10.18632/oncotarget.443 · Cited by 140
Maslah, N., Salomao, N., Drevon, L., Verger, E., Partouche, N., Ly, P., Aubin, P., Naoui, N., Schlageter, M.-H., Bally, C., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.218453 · Cited by 132
Perdrix, A., Najem, A., Saussez, S., Awada, A., Journe, F., Ghanem, G., & Krayem, M. (2017) · Cancers · doi:10.3390/cancers9120172 · Cited by 126
Li, Y., Mao, Y., Brandt-Rauf, P. W., Williams, A. C., & Fine, R. L. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0206 · Cited by 57
Ali, D., Mohammad, D. K., Mujahed, H., Jonson‐Videsäter, K., Nore, B., Paul, C., & Lehmann, S. (2016) · British Journal of Haematology · doi:10.1111/bjh.14036 · Cited by 49
Tessoulin, B., Descamps, G., Dousset, C., Amiot, M., & Pellat-Deceunynck, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00128 · Cited by 31
Research works printed but not linked: 77
- Haupt, 1997, Mdm2 promotes the rapid degradation of p53, Nature, 387, 296, 10.1038/387296a0 · DOI · Paper page
- Zhou, 2019, Mutant p53 in cancer therapy—the barrier or the path, J. Mol. Cell Biol., 11, 293, 10.1093/jmcb/mjy072 · DOI · Paper page
- Dittmer, 1993, Gain of function mutations in p53, Nat. Genet., 4, 42, 10.1038/ng0593-42 · DOI · Paper page
- Leroy, 2014, TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade, Hum. Mutat., 35, 672, 10.1002/humu.22552 · DOI · Paper page
- Dearth, 2007, Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers, Carcinogenesis, 28, 289, 10.1093/carcin/bgl132 · DOI · Paper page
- Zenz, 2008, Molecular diagnostics in chronic lymphocytic leukemia—Pathogenetic and clinical implications, Leuk. Lymphoma, 49, 864, 10.1080/10428190701882955 · DOI
- Zhao, 2010, Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA, Cell Cycle, 9, 1847, 10.4161/cc.9.9.11545 · DOI · Paper page
- Konopleva, 2020, MDM2 inhibition: An important step forward in cancer therapy, Leukemia, 34, 2858, 10.1038/s41375-020-0949-z · DOI · Paper page
- Schulz-Heddergott, R., and Moll, U. (2018). Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target. Cancers, 10. · DOI · Paper page
- Wang, 2011, Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP, J. Cell. Biochem., 112, 509, 10.1002/jcb.22941 · DOI · Paper page
- Foggetti, 2017, Gambogic acid counteracts mutant p53 stability by inducing autophagy, Biochim. Biophys. Acta Mol. Cell Res., 1864, 382, 10.1016/j.bbamcr.2016.11.023 · DOI
- Foggetti, 2019, Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival, Biosci. Rep., 39, BSR20181345, 10.1042/BSR20181345 · DOI · Paper page
- Vassilev, 2004, In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2, Science, 303, 844, 10.1126/science.1092472 · DOI · Paper page
- Selivanova, 2014, Wild type p53 reactivation: From lab bench to clinic, FEBS Lett., 588, 2628, 10.1016/j.febslet.2014.03.049 · DOI · Paper page
- Trepel, 2010, Targeting the dynamic HSP90 complex in cancer, Nat. Rev. Cancer, 10, 537, 10.1038/nrc2887 · DOI · Paper page
- Li, 2011, Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells, Mol. Cancer Res., 9, 577, 10.1158/1541-7786.MCR-10-0534 · DOI · Paper page
- Alexandrova, 2017, Depleting stabilized GOF mutant p53 proteins by inhibiting molecular folding chaperones: A new promise in cancer therapy, Cell Death Differ., 24, 3, 10.1038/cdd.2016.145 · DOI
- Cheung, 2009, The significance of TP53 in lymphoid malignancies: Mutation prevalence, regulation, prognostic impact and potential as a therapeutic target, Br. J. Haematol., 146, 257, 10.1111/j.1365-2141.2009.07739.x · DOI
- Gaidano, 1991, p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. USA, 88, 5413, 10.1073/pnas.88.12.5413 · DOI · Paper page
- Nahi, 2008, Mutated and non-mutated TP53 as targets in the treatment of leukaemia, Br. J. Haematol., 141, 445, 10.1111/j.1365-2141.2008.07046.x · DOI · Paper page
- Agirre, 2003, TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia, Mol. Carcinog., 38, 201, 10.1002/mc.10159 · DOI · Paper page
- Chng, 2007, Clinical significance of TP53 mutation in myeloma, Leukemia, 21, 582, 10.1038/sj.leu.2404524 · DOI
- Chiorazzi, 2005, Chronic Lymphocytic Leukemia, N. Engl. J. Med., 352, 804, 10.1056/NEJMra041720 · DOI · Paper page
- Hallek, 2018, Chronic lymphocytic leukaemia, Lancet, 391, 1524, 10.1016/S0140-6736(18)30422-7 · DOI · Paper page
- Gentile, 2018, Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab, Leukemia, 32, 1869, 10.1038/s41375-018-0100-6 · doi:10.1038/s41375-018-0100-6
- Stilgenbauer, 2000, Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia, N. Engl. J. Med., 343, 1910, 10.1056/NEJM200012283432602 · DOI · Paper page
- Rossi, 2014, Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia, Blood, 123, 2139, 10.1182/blood-2013-11-539726 · DOI · Paper page
- Monti, 2020, Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?, Front. Oncol., 10, 593383, 10.3389/fonc.2020.593383 · DOI
- Buccheri, 2018, Prognostic and therapeutic stratification in CLL: Focus on 17p deletion and p53 mutation, Ann. Hematol., 97, 2269, 10.1007/s00277-018-3503-6 · DOI
- Rossi, 2009, The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness, Clin. Cancer Res., 15, 995, 10.1158/1078-0432.CCR-08-1630 · DOI · Paper page
- Zenz, 2010, TP53 mutation profile in chronic lymphocytic leukemia: Evidence for a disease specific profile from a comprehensive analysis of 268 mutations, Leukemia, 24, 2072, 10.1038/leu.2010.208 · DOI · Paper page
- Stilgenbauer, 2014, Gene mutations and treatment outcome in chronic lymphocytic leukemia: Results from the CLL8 trial, Blood, 123, 3247, 10.1182/blood-2014-01-546150 · DOI · Paper page
- Cymbalista, 2016, Genetic profiling of CLL: A ‘TP53 addict’ perspective, Cell Death Dis., 7, e2042, 10.1038/cddis.2015.415 · doi:10.1038/cddis.2015.415
- Malcikova, 2018, ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation, Leukemia, 32, 1070, 10.1038/s41375-017-0007-7 · DOI · Paper page
- Burger, 2015, Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia, N. Engl. J. Med., 373, 2425, 10.1056/NEJMoa1509388 · DOI · Paper page
- Burger, 2020, Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study, Leukemia, 34, 787, 10.1038/s41375-019-0602-x · DOI · Paper page
- Shanafelt, 2019, Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia, N. Engl. J. Med., 381, 432, 10.1056/NEJMoa1817073 · DOI · Paper page
- Woyach, 2018, Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL, N. Engl. J. Med., 379, 2517, 10.1056/NEJMoa1812836 · DOI · Paper page
- Furman, 2014, Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia, N. Engl. J. Med., 370, 997, 10.1056/NEJMoa1315226 · DOI · Paper page
- Sharman, 2019, Final Results of a Randomized, Phase III Study of Rituximab with or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia, J. Clin. Oncol., 37, 1391, 10.1200/JCO.18.01460 · DOI · Paper page
- Zhang, 2020, Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): Follow-up results from a multicentre, open-label, randomised, phase 3 trial, Lancet Oncol., 21, 1188, 10.1016/S1470-2045(20)30443-5 · DOI · Paper page
- Morabito, 2020, TP53 dysfunction in chronic lymphocytic leukemia: Clinical relevance in the era of B-cell receptors and BCL-2 inhibitors, Expert Opin. Investig. Drugs, 29, 869, 10.1080/13543784.2020.1783239 · DOI
- Ahn, I.E., Tian, X., Ipe, D., Cheng, M., Albitar, M., Tsao, L.C., Zhang, L., Ma, W., Herman, S.E.M., and Gaglione, E.M. (2020). Prediction of Outcome in Patients with Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. J. Clin. Oncol. · DOI · Paper page
- Monti, 2020, Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: Results of the O-CLL1 study in early stage patients, Sci. Rep., 10, 18427, 10.1038/s41598-020-75364-3 · doi:10.1038/s41598-020-75364-3
- Best, 2009, A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease, Leukemia, 23, 212, 10.1038/leu.2008.260 · doi:10.1038/leu.2008.260
- Bykov, 2002, Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: A statistical analysis of information in the National Cancer Institute database, Carcinogenesis, 23, 2011, 10.1093/carcin/23.12.2011 · DOI · Paper page
- Wang, 2007, PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax, Biochem. Biophys. Res. Commun., 352, 203, 10.1016/j.bbrc.2006.11.006 · DOI · Paper page
- Liang, 2009, PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein, Int. J. Oncol., 35, 1015
- Zandi, 2011, PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53, Clin. Cancer Res., 17, 2830, 10.1158/1078-0432.CCR-10-3168 · DOI · Paper page
- Messina, 2012, Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells, Int. J. Cancer, 130, 2259, 10.1002/ijc.26228 · DOI · Paper page
- Farhadi, 2017, PRIMA-1 induces caspase-mediated apoptosis in acute promyelocytic leukemia NB4 cells by inhibition of nuclear factor-κB and downregulation of Bcl-2, XIAP, and c-Myc. Anticancer, Drugs, 28, 51
- Lee, 2006, Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells, Biochem. Biophys. Res. Commun., 349, 1117, 10.1016/j.bbrc.2006.08.152 · DOI
- Chipuk, 2003, Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription, Cancer Cell, 4, 371, 10.1016/S1535-6108(03)00272-1 · DOI · Paper page
- Lambert, 2010, Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis, Oncogene, 29, 1329, 10.1038/onc.2009.425 · DOI · Paper page
- Magrini, 2008, PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells, J. Cell. Biochem., 104, 2363, 10.1002/jcb.21794 · DOI
- Izetti, 2014, PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines, Investig. New Drugs, 32, 783, 10.1007/s10637-014-0090-9 · DOI
- Liu, 2015, APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoalima, Gut, 64, 1506, 10.1136/gutjnl-2015-309770 · DOI · Paper page
- Deben, 2016, APR-246 (PRIMA-1 MET) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines, Cancer Lett., 375, 313, 10.1016/j.canlet.2016.03.017 · DOI
- Nahi, 2004, Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion, Br. J. Haematol., 127, 285, 10.1111/j.1365-2141.2004.05210.x · DOI · Paper page
- Donehower, 2019, Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas, Cell Rep., 28, 1370, 10.1016/j.celrep.2019.07.001 · DOI · Paper page
- Nahi, 2006, PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion, Br. J. Haematol., 132, 230, 10.1111/j.1365-2141.2005.05851.x · DOI · Paper page
- Ali, 2011, APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells, Eur. J. Haematol., 86, 206, 10.1111/j.1600-0609.2010.01557.x · DOI · Paper page
- Wassman, 2013, Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53, Nat. Commun., 4, 1407, 10.1038/ncomms2361 · DOI · Paper page
- Saha, 2013, PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa, Mol. Cancer Ther., 12, 2331, 10.1158/1535-7163.MCT-12-1166 · DOI · Paper page
- Bao, 2011, PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo, Cell Cycle Georget. Tex, 10, 301, 10.4161/cc.10.2.14538 · DOI · Paper page
- Supiot, 2008, PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status, Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol., 86, 407, 10.1016/j.radonc.2008.01.001 · DOI
- Shi, 2008, In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249, Carcinogenesis, 29, 1428, 10.1093/carcin/bgm266 · DOI · Paper page
- Grellety, T., Laroche-Clary, A., Chaire, V., Lagarde, P., Chibon, F., Neuville, A., and Italiano, A. (2015). PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53. BMC Cancer, 15. · DOI · Paper page
- Teoh, 2016, PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation, Oncotarget, 7, 61806, 10.18632/oncotarget.11241 · DOI · Paper page
- Lisek, 2018, Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells, Oncotarget, 9, 20508, 10.18632/oncotarget.24974 · DOI · Paper page
- Saha, 2016, MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc, Oncotarget, 7, 7149, 10.18632/oncotarget.6880 · DOI · Paper page
- Russo, 2013, PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53, Biochim. Biophys. Acta, 1833, 1904, 10.1016/j.bbamcr.2013.03.020 · DOI
- Russo, 2010, PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells, Biochem. Biophys. Res. Commun., 402, 345, 10.1016/j.bbrc.2010.10.031 · DOI
- Jaskova, 2020, PRIMA-1MET cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells, Leuk. Res., 89, 106288, 10.1016/j.leukres.2019.106288 · DOI
- Sallman, 2020, To target the untargetable: Elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia, Haematologica, 105, 1470, 10.3324/haematol.2020.249060 · DOI · Paper page
- Jain, 2019, Ibrutinib and Venetoclax for First-Line Treatment of CLL, N. Engl. J. Med., 380, 2095, 10.1056/NEJMoa1900574 · DOI · Paper page
- Rozovski, 2016, Metabolism pathways in chronic lymphocytic leukemia, Leuk. Lymphoma, 57, 758, 10.3109/10428194.2015.1106533 · DOI
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
“386 400 However, growing evidence suggests that APR-246 exerts its effects through a multitude of pathways independent of p53, 401 – 404 such as downregulating glutathione concentrations in tumor cells, 405,406 regulating oxidation-reduction homeostasis 407 – 409 in tumor cells to trigger…”
Backgroundp53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Menichini, P., Monti, P., Speciale, A., Cutrona, G., Matis, S., Fais, F., Taiana, E., Neri, A., Bomben, R., Gentile, M., Gattei, V., Ferrarini, M., Morabito, F., & Fronza, G.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-01-07
- Volume
- 10
- Issue
- 1
- Pages
- 98
- ISSN
- 2073-4409
- Cited by
- 48
- References
- 19
- Language
- en
- Funders
- Associazione Italiana per la Ricerca sul Cancro (Grant 5 x mille n.9980, n.14326, n.15426, and n. 5506)
- AIRC and Fondazione CaRiCal co-financed Multi-Unit Regional Grant 2014 (n.16695)
- Italian Ministry of Health 5x1000 (Funds 2013, 2014, 2015, 2016)
- Italian Ministry of Health Current Reserach (funds 2016)
- Italian Ministry of Health Alleanza contro il Cancro (ACC) (Hematology network)
- Compagnia S. Paolo Turin, Italy (project 2017.0526)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.